KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Cash & Equivalents (2016 - 2026)

Bio-Rad Laboratories has reported Cash & Equivalents over the past 18 years, most recently at $507.2 million for Q1 2026.

  • Quarterly Cash & Equivalents fell 2.72% to $507.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $507.2 million through Mar 2026, down 2.72% year-over-year, with the annual reading at $529.8 million for FY2025, 8.54% up from the prior year.
  • Cash & Equivalents was $507.2 million for Q1 2026 at Bio-Rad Laboratories, down from $529.8 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $802.3 million in Q1 2022 and troughed at $369.3 million in Q2 2025.
  • The 5-year median for Cash & Equivalents is $457.8 million (2023), against an average of $478.2 million.
  • Year-over-year, Cash & Equivalents plummeted 42.15% in 2023 and then grew 20.88% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $434.2 million in 2022, then fell by 7.0% to $403.8 million in 2023, then increased by 20.88% to $488.1 million in 2024, then rose by 8.54% to $529.8 million in 2025, then dropped by 4.27% to $507.2 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Cash & Equivalents are $507.2 million (Q1 2026), $529.8 million (Q4 2025), and $395.8 million (Q3 2025).